Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
30 hedge funds and large institutions have $37.4M invested in Bellerophon Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 29 → 30 (+1)
54% less capital invested
Capital invested by funds: $81.8M → $37.4M (-$44.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$85.7K |
| 2 |
LPL Financial
San Diego,
California
|
+$46.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$43.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.1K |
| 5 |
Millennium Management
New York
|
+$38.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.57M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$594K |
| 3 |
JP Morgan Chase
New York
|
-$574K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$562K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$254K |
BLPH Hedge Fund Activity: Q3 2018 in Review
30 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q3 2018, worth a combined $37.4M — down 54% from $81.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLPH positions and 6 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $85.7K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.57M sold.
- 30 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q3 2018, up from 29 in Q2 2018.
- Funds reported $37.4M of Bellerophon Therapeutics, Inc. stock for Q3 2018, down 54% quarter-over-quarter.
- 7 funds opened new Bellerophon Therapeutics, Inc. positions in Q3 2018 and 6 closed out, a net change of +1 holder.
- The largest Bellerophon Therapeutics, Inc. buyer in Q3 2018 was Renaissance Technologies, an estimated $85.7K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q3 2018 was Fidelity Investments, an estimated $1.57M sold.
Based on aggregated 13F filings for Q3 2018.